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Abstract
Background. Regional citrate anticoagulation is a very ef-
fective anticoagulation method for haemodialysis. How-
ever, it is not widely used, primarily due to the risk of
hypocalcaemia. We studied citrate and calcium kinetics
to better understand safety aspects of this anticoagulation
method.
Methods. During 15 haemodialysis treatments with a
calcium-free dialysis solution, citrate was infused pre-
dialyser and calcium was substituted post-dialyser. Sys-
temicandextracorporealcitrateandcalciumconcentrations
were repeatedly measured to calculate citrate and calcium
pharmacokinetics.
Results. Removal by dialysis constituted the major elimi-
nation pathway of citrate (83 ± 5%). Systemic citrate load
and concentrations were low (17 ± 7 mmol/4 h, 0.3 ±
0.15 mmol/l). Combined use of calcium-free dialysate and
citrate infusion increased diffusible calcium to 80% of to-
tal calcium and induced substantial dialytic loss of calcium
(43±4mmol/4h).Sincecalciumwassubstituted,systemic
calcium balances were positive (∼+5 mmol) and concen-
trations stable. Calcium supplementation correlated with
calcium dialytic losses, which in turn were dependent on
total calcium and haematocrit.
Conclusions. When using calcium-free dialysate during
citrate anticoagulation, hypocalcaemia is very likely unless
calciumisre-infused,becauselargeamountsofcalciumare
lost in the dialysate. However, an accumulation of citrate
in the patient’s systemic circulation is an unlikely cause
of hypocalcaemia since most of the citrate is removed by
dialysis. Calcium substitution and monitoring are the most
important safety measures. We propose a rational approach
based on haematocrit and total calcium for the choice of
the starting calcium supplementation rate.
Keywords: calcium; citrate; dialysis; pharmacokinetics; regional
anticoagulation
Introduction
Systemic heparinization is the anticoagulation of choice in
stable patients on chronic haemodialysis. However, if a pa-
tientisatincreasedriskofbleeding,e.g.aftersurgery,inthe
presence of coagulopathy, in pericarditis or in patients ac-
tively bleeding, systemic anticoagulation with heparin can
cause fatal haemorrhage [1]. In these cases regional citrate
anticoagulation (RCA) has long been advocated as an al-
ternative [2]. The anticoagulation effect of citrate is due
to formation of complexes with calcium ions, which are
essential cofactors of the coagulation process. The bene-
fit of this method is that anticoagulation is limited to the
dialysis circuit. The most dangerous complication is sys-
temic hypocalcaemia, which may be even life threatening.
Cardiac collapse has previously been described after an
application of citrate anticoagulation during dialysis [3].
Systemic calcium levels may be decreased during regional
citrate anticoagulation by two mechanisms. The first possi-
ble mechanism of hypocalcaemia is citrate infusion. Citrate
infusedintothearteriallineofthedialysiscircuitmayreach
the patient’s systemic circulation although it is partially re-
moved by dialysis. Citrate in the systemic circulation binds
ionizedcalciumandmayinducehypocalcaemia.Thiseffect
may be more pronounced in the case of liver dysfunction
with impaired citrate metabolism or with limited dialysate
elimination during continuous renal replacement therapies
(CRRT) [4]. The second mechanism of hypocalcaemia is
the dialytic removal of calcium due to the use of calcium-
free dialysate. Many RCA protocols for haemodialysis uti-
lize calcium-free dialysis fluid, because this prevents cal-
cium uptake from the dialysate and the reduction of the
anticoagulation effect. Exact quantities of citrate and cal-
cium removed by dialysis are usually unknown since they
are not routinely measured. The prediction of the amounts
removed is even more complex as they depend on many pa-
rameters e.g. the characteristics of the dialyser used, blood
and dialysate flow rates or the dialysable concentration of
calcium inside the dialyser.
Apart from liver failure, little is known about other fac-
tors that may contribute to the development of hypocal-
caemia during RCA in stable dialysis patients. For this
reason we studied citrate pharmacokinetics and its effect
on calcium levels during RCA in stable dialysis patients
without signs of liver failure. The goal was to identify pa-
rameters contributing to the risk of hypocalcaemia and thus
to provide more precise guidelines for the safe application
of this anticoagulation method.
C   The Author [2009].
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Table 1. Clinical characteristics of patients
Patient Age/sex Diagnoses Indication for citrate anticoagulation No. of treatments/vascular access
1. 70/F CRF, M. Wegener Haemoptysis 2/catheter
2. 72/F CRF, M. Wegener After surgery 2/a-v fistula
3. 53/M CRF; hypertension After surgery 1/a-v fistula
4. 52/M ARF, M. Wegener Haemoptysis 3/catheter
5. 79/F CRF; hypertension, diabetes mellitus After surgery 1/a-v fistula
6. 55/M CRF, polycystic kidney disease After surgery 1/a-v fistula
7. 64/M CRF, M. Wegener History of heparin-induced bleeding 1/a-v fistula
8. 68/M CRF, hypertension, chronic pyelonephritis After thyroid biopsy 1/a-v fistula
9. 69/M ARF after heart surgery After surgery 2/catheter
10. 51/M CRF, chronic glomerulonephritis Immediately before surgery 1/a-v fistula
Subjects and methods
Patients
Patients (n = 10) with renal failure requiring dialysis and increased risk of
bleeding participated in the study after giving written informed consent.
The clinical characteristics of the patients are summarized in Table 1. All
patients were in stable clinical condition and were treated in the dialysis
unit of the Munich University Hospital. The majority of patients were at
risk of bleeding due to recent surgery. None of the patients received blood
or blood products or were treated with plasma exchange in the 24 h prior
to the study. Patients were dialysed with citrate anticoagulation as long
as an increased bleeding risk existed (1–3 dialysis treatments per patient).
In total 15 haemodialysis treatments were investigated. The study was
carried out according to the Declaration of Helsinki and the protocol was
approved by the local ethics committee.
Haemodialysis
Dialysis was carried out using a modified 4008 dialysis machine with
citrate module (Prometheus
R , Fresenius Medical Care, Bad Homburg,
Germany)andhigh-fluxdialysers(FreseniusMedicalCare,BadHomburg,
Germany, FX50: 5 treatments, F60S: 10 treatments, both dialysers have
similarinvitroclearancesforurea,189and185ml/minforQB 200ml/min,
respectively).
Blood pump speed during citrate anticoagulation was limited by the
Prometheus device to 200 ml/min to reduce citrate load and accumulation.
This resulted in the mean effective blood flow rate of 183 ± 2 ml/min.
Effective blood flow rate was automatically estimated by one of the mod-
ules of the Prometheus device. We recorded effective blood flow rate as
displayed by the dialysis machine at the beginning of dialysis, during each
blood sampling and shortly before the end of dialysis, i.e. at least seven
times during every treatment. The variations were minimal (± 1 ml/min
per session). Ultrafiltration rate (492 ± 76 ml/h) was adjusted according
to the patients’ needs. The flow and temperature of the calcium-free dial-
ysis solution (SK-F 419/1, magnesium = 0.5 mmol/l, Fresenius Medical
Care,BadHomburg,Germany)was500ml/minand37◦,respectively.The
initial bicarbonate concentration of 32 mmol/l was adjusted depending on
the measured systemic pH and was on average reduced to 28 mmol/l.
Vascular access was either via an arterio-venous fistula (eight treatments)
or a double lumen Shaldon catheter (seven treatments) (see Table 1). The
majority of haemodialysis sessions lasted 4 h. Two treatments were suc-
cessfully carried out over 5 and 6 h, since two patients needed a longer
time to achieve the required ultrafiltration volume.
Anticoagulation
The citrate module of the Prometheus
R  device, consisting of citrate and
calcium infusion pumps, was used for anticoagulation. The tri-sodium cit-
rate solution (500 mmol/l) was infused into the arterial line prior to the
blood pump at a dose of 3.3 mmol/l of blood flow. The calcium chloride
solution (500 mmol/l) was infused into the venous line at an initial dose
of 1.1 mmol/le of blood flow. Ionized calcium was measured repeatedly
and calcium infusion rate was adapted to maintain initial calcium concen-
tration. If ionized calcium was out of the normal range in the pre-dialysis
measurement, then calcium infusion was aimed to reach the normal range
(1.1–1.3mmol/l).Attheendofthetreatment,weexaminedcitrateandcal-
cium containers. The infused volumes of solutions were always consistent
with the infusion pump settings and the duration of treatment confirming
the accuracy of the citrate and calcium pumps.
Laboratory tests
Blood samples were taken from the arterial line of the extracorporeal
circuit prior to the citrate infusion site (‘arterial samples’) at time points
0m i n ,+15 min, +45 min, +105 min, +165 min, +225 min. Three post-
filter samples were taken from the venous return line during HD (+45
min, +165 min, +225 min). Four post-HD samples (‘post0’min, +post15
min, +post30 min, +post240 min) were taken in addition.
All samples were analysed for citrate concentration, electrolytes (total
calcium, ionized calcium, magnesium, sodium and chloride) and acid–
base status. Additionally, in the pre-treatment samples haematocrit and
protein concentration were measured.
The samples for blood gas analysis and ionized calcium were collected
in lithium–heparin syringes and immediately processed in the dialysis
unit using RapidlabTM 348, Bayer Diagnostics, Munich, Germany. Total
calcium was measured photometrically. Other electrolytes, haematocrit
and protein concentrations were measured using standard laboratory tech-
niques. Citrate concentrations were determined using an enzymatic assay
(R-Biopharm, Darmstadt, Germany). All laboratory tests were carried out
by the same person using identical procedures and equipment.
Calculations
As citrate does not enter erythrocytes [5], we calculated plasma water
clearance of citrate, KCit, using the formula [6]
KCit =
Cin − Cout
Cin
∗ QP + UF
Cout
Cin
,
where Cin and Cout are plasma water concentrations of citrate at the inlet
and the outlet of the dialyser, respectively. The inlet concentration was the
measured ‘arterial’ concentration (Cart) corrected for the infused amount
of citrate [CSol
∗QCit/QP + QCit] and water. The outlet concentration was
themeasuredpost-filterconcentration.Allmeasuredserumconcentrations
were converted to plasma water concentration.
QP: plasma water flow rate at the dialyzer inlet [QB
∗
(1−haematocrit)∗(1−protein conc./100) + QCit].
CSol: concentration of citrate solution
QCit: citrate solution flow rate
UF: ultrafiltration rate
In addition, we calculated the removal of citrate mass by dialysis (ex-
traction ratio) from an a-v difference of the dialyser including the effect of
ultrafiltration =
Cin∗QP−Cout(QP−UF)
Cin∗QP . The amount of citrate returning to
the patient equal to net citrate dose was assessed as the difference between
the infused and the removed citrate.
Citrate half-life was calculated using citrate concentrations from the
first three post-treatment samples according to first-order kinetics. The
apparent distribution volume of citrate was assessed using software for
the modelling and simulation of dynamic systems (software VisSim 4.5,
Visual Solutions Inc., Westford, MA, USA). This software was also used
to validate the value of citrate half-life.
Theflux(loss)ofcalciumacrossthedialysermembranewascalculated
from the concentration gradient of total calcium at the inlet and the outlet2246 J. Kozik-Jaromin et al.
of the dialyser (arterial and post-filter samples, respectively), which was
corrected for ultrafiltration. The net balance was the difference between
the infused and the removed calcium.
In addition, diffusible calcium concentration was calculated. Calcium
in the blood is partially bound to proteins and this calcium cannot be
removed by dialysis. Thus, diffusible calcium represents calcium that is
notboundtoproteinsandcanpassthroughthedialysermembrane.During
dialysis with citrate anticoagulation, diffusible calcium consists mainly
of citrate–calcium complexes. Since citrate in the dialyser also consists
mainly of citrate–calcium complexes, the measured clearance of citrate is
a good estimate of the clearance of citrate-calcium complexes. Therefore,
the concentration of diffusible calcium in the dialyser was estimated from
the flux of calcium and the clearance of citrate [Caflux/KCit]. Diffusible
calcium was 80 ± 3% of total calcium in the blood inside the dialyser
capillaries.
Calciumlossisveryimportanttoguidethesubstitutionrateofcalcium,
but its direct measurement is not practicable in routine dialysis. Therefore,
we developed a method to estimate calcium loss using clinically available
parameters: total calcium concentration, haematocrit, protein concentra-
tion, blood flow rate, dialysate flow rate and mass transfer area coefficient
of citrate (F60S: KoA = 337 ml/min, own unpublished data).
Calcium removal was calculated from standard equation of a flux (flux
= diffusible solute conc. ∗ clearance) using KoA of citrate for the calcula-
tion of the clearance and diffusible calcium equal to 80% of total calcium,
according to the results of this study:
Caloss = 0.8 ∗ Catotal ∗ K,
where K is the clearance of citrate (or citrate–calcium complexes) calcu-
lated according to equation proposed by Sargent and Gotch [7]:
K =
e

1
QP
− 1
QD

∗KoA
− 1
e

1
QP
− 1
QD

∗KoA
−
QP
QD
∗ QP
⇒ KoA =
Ln

QE ∗
K−QD
QD∗(K−QE)

1
QE − 1
QD
,
where QD is the dialysate flow rate and QP is the plasma water flow rate.
The losses calculated according to this equation were compared with
the measurements in the first treatment hour (+45 min samples).
Statistical analysis
Dataarepresentedasmean±standarddeviation.Thet-testforpairedsam-
ples or Wilcoxon’s signed-rank test was used as appropriate to compare
differences between pre- and post-HD values. Independent data samples
were evaluated with a t-test or Wilcoxon’s rank-sum test. The normality
of sample distribution was checked by the Kolmogorov–Smirnov test with
Lilliefors’ correction. Correlations were measured with the use of Pear-
son’s and/or Spearman’s correlation coefficient. A value of P < 0.05 was
considered statistically significant (two-tailed tests). Statistical analysis
was performed using SigmaStat software version 2.03.
Results
Anticoagulation
All treatments were carried out without adverse events.
The extracorporeal circuit was effectively anticoagulated
during all treatments. No complete occlusion of the sys-
temoccurred.Visualinspectionrevealedminimalthrombus
formation in 5 out of 15 haemodialysis sessions. All clots
observed were located in the ‘arterial’ part of the extracor-
poreal circuit (arterial chamber: 4, arterial sampling site:
1 and filter inlet: 1). During one dialysis two clots were
formed simultaneously (in the arterial chamber and in the
filter).Inthetreatmentsaffected,post-filterionizedcalcium
was always below the detection limit (<0.2 mmol/l).
Fig. 1. Systemic citrate concentration (mmol/l) during and after
haemodialysis.
Table 2. Laboratory parameters: haematocrit, total protein, citrate, elec-
trolytes, pH and bicarbonate (pH and bicarbonate shown separately for
patients with different vascular access: a-v fistula or catheter)
Pre-dialysis Post-dialysis
Haematocrit 0.31 ± 0.06 –
Total protein (g/dl) 5.9 ± 1.0 –
Albumin (g/dl) 3.5 ± 0.6 –
Citrate (mmol/l) 0.12 ± 0.06 0.25 ± 0.07
∗
Ionized calcium (mmol/l) 1.10 ± 0.1 1.19 ± 0.09∗
Total calcium (mmol/l) 2.17 ± 0.16 2.20 ± 0.17
Sodium (mmol/l) 142 ± 4 139 ± 2
Magnesium (mmol/l) 0.9 ± 0.16 0.8 ± 0.09
Chloride (mmol/l) 100 ± 5 101 ± 2
pH (fistula) 7.41 ± 0.03 7.46 ± 0.02
pH (catheter) 7.41 ± 0.03 7.43 ± 0.04
Actual bicarbonate (mmol/l) (fistula) 21 ± 2.4 24± 1.7
Actual bicarbonate (mmol/l) (catheter) 25 ± 2.8 26 ± 2.0
∗P < 0.05 for the difference between pre- and post-dialysis values.
Systemic citrate concentration
Systemic citrate concentration increased steadily during
dialysis from 0.12 ± 0.05 mmol/l (pre-HD) to 0.31 ±
0.15mmol/l(+225min)butmostrapidlyinthefirst40min
of HD (Figure 1, Table 2). The highest measured value was
0.72 mmol/l. Concentrations measured 4 h after the treat-
ment were comparable to baseline (0.10 ± 0.04 mmol/l)
indicating that citrate did not accumulate between HD
sessions.
Citrate removal by the dialyser and net citrate dose
The removal of citrate into the dialysate was very efficient
amounting to 83 ± 5% of the citrate entering the dialyser
(i.e. the externally infused citrate and the citrate present in
the systemic circulation). The plasma water clearance of
citrate was 98 ± 1 0m l / m i n .D u r i n g4ho fH D ,an e tc i t r a t e
dose delivered to the systemic circulation of the patient was
17 ± 7 mmol (Table 3).Kinetics of citrate anticoagulation during dialysis 2247
Table 3. Pharmacokinetic data
Plasma water flow rate (ml/min) 118 ± 11
Citrate plasma water clearance
(ml/min)
98 ± 10
Net citrate dose per 4 h of HD
(mmol)
17 ± 7
Citrate mass removal (%) 83 ± 5
Citrate half-life (min) 60 ± 29
Citrate distribution volume, litres
(% of body weight)
41 ± 22 (54 ± 18)
Calcium removal rate, mmol/min
(mg/min)
0.18 ± 0.02 (7.2 ± 0.8)
Calcium loss per 4 h of HD, mmol
(mg)
43 ± 4 (1720 ± 160)
Calcium substitution per 4 h of
HD, mmol (mg)
48 ± 1 (1920 ± 40)
Distribution volume and metabolism of citrate
After 4 h of treatment, the apparent distribution volume of
citrate was 41 ± 22 l, which corresponded to 54 ± 18% of
the body weight. The measured systemic citrate concentra-
tions best fitted with a two-compartmental model suggest-
ing that in the first 2 h citrate distribution was not yet in a
steady state. In all patients citrate was readily metabolized
with a mean half-life of 60 ± 29 min. Citrate half-life did
not correlate with body weight (Pearson: r = 0.175, P =
0.568).
Unusual case of citrate pharmacokinetics
In one patient with normal liver function, abnormal cit-
rate pharmacokinetics were observed and therefore this
patient was evaluated separately. In this patient, the cit-
rate concentration at baseline was ∼5-fold higher than
the average of the remaining patients (0.63 mmol/l versus
0.12 mmol/l). The blood samples of this patient were anal-
ysed three times with high reproducibility excluding possi-
ble lab errors. Citrate concentrations during haemodialysis
remained relatively constant in this patient, probably due
to very efficient removal of citrate into the dialysate (90%
of the amount entering the dialyser). Citrate anticoagula-
tion was performed without side effects in this patient. The
reason for this high baseline citrate concentration remains
elusive.Increasedcitratelevelswerereportedsofarinbone
diseasesassociatedwithosteolysis[8].However,atthetime
of the study there was no clinical evidence of bone disease
in this patient.
Systemic ionized and total calcium concentrations
Clinical symptoms of hypo- or hypercalcaemia were not
observed.Calciumvalueswerestableduringalltreatments.
Only 7 out of 78 measured ionized calcium values during
HDwereoutoftherange:1.0–1.3mmol/l(min:0.9mmol/l,
max: 1.38 mmol/l).
Diffusible calcium and protein-bound calcium
In the systemic blood under normal conditions, ∼40% of
calcium is bound to proteins and 60% of calcium can cross
the dialyser membrane (diffusible calcium). A shift of cal-
ciumionsfromproteinbindingtocitratecomplexes,chang-
Fig. 2. Correlation between measured calcium removal and removal cal-
culated from KoA (mmol/min).
ing the proportion of bound to diffusible calcium, is pos-
sible in the extracorporeal circuit during RCA. Our results
demonstrate that an important shift of calcium ions from
proteins actually occurs in the extracorporeal circuit during
RCA, which decreases protein-bound calcium to 20 ± 3%,
increasing diffusible calcium to 80 ± 3% of total calcium.
Measured calcium removal
Of the 80 ± 3% of calcium that could cross the dialyser
membrane, 64 ± 5% moved to the dialysis solution leading
to average calcium removal rate of 0.18 ± 0.02 mmol/min.
This rate varied among the patients by almost 50%, rang-
ing from 0.13 to 0.22 mmol/min. Calcium loss correlated
strongly with the product of total calcium concentration
and the measured citrate clearance, r = 0.942, P < 0.001.
Linear regression yielded the equation Caloss =− 0.00546
+ 0.875∗Catot
∗KCit, r2 = 0.887, P < 0.001. Interestingly,
ionized calcium concentration was less predictive of cal-
cium loss than total calcium (r = 0.633, r2 = 0.401, P =
0.001, Caloss = 0.0705 + 0.982∗Caion
∗KCit).
Calcium removal calculated from KoA
CalciumlosscalculatedusingKoAcorrelatedstronglywith
the measured value: r = 0.832; r2 = 0.692, P < 0.001,
Caloss-calc. = 0.0696 + 0.667∗Caloss-meas. (Figure 2) and
was slightly higher than the measured one on average by
0.01 mmol/min.
Only in one patient was calculated calcium removal was
slightly below the measured value (by 0.009 mmol/min).
This patient had the lowest protein concentration (4.3 g/dl
versus all other patients ≥ 5.5 g/dl) resulting in low protein
binding of calcium and in a higher proportion of diffusible
calcium (84% versus average value 80%). Therefore, cal-
cium removal was higher than expected.
Post-filter calcium concentrations
Post-filter total calcium concentrations were decreased to
0.8±0.1mmol/l(arterialconcentration:2.2±0.2mmol/l).2248 J. Kozik-Jaromin et al.
All measured post-filter ionized calcium concentrations
were at or below detection limit (≤0.2 mmol/l).
Calcium supplementation
Calcium supplementation was initially proportional to the
effectivebloodflow(0.205±0.005mmol/min).Duringthe
majority of treatments, supplementation rate was slightly
decreased to keep the pre-dialysis ionized calcium value.
In the fourth treatment hour, it was on average 0.195 ±
0.005 mmol/min. Total amount of calcium supplemented
(mmol) correlated significantly with total amount of cal-
cium removed into the dialysate (mmol), r = 0.797,
P < 0.001.
Net balance of calcium
In 13 out of 15 treatments, the initial calcium supplemen-
tation rate was higher than the calcium removal rate and
thesesessionsendedwithapositivecalciumbalance(mean:
5 mmol/per HD, max: 17 mmol/per HD). Positive calcium
balances did not increase systemic ionized or total calcium
concentrations accordingly. No correlation between posi-
tive net balance and calcium concentrations was observed
(total calcium: r = 0.397, P = 0.143, ionized calcium: r =
−0.114, P = 0.685). In contrast, the modest negative cal-
cium balance observed in two patients (up to −1 mmol/per
HD) was associated with small post-dialytic decreases in
the total calcium level and in one patient also in ionized
calcium.
Concentrations of other electrolytes and acid–base status
Systemic levels of other electrolytes (sodium, magnesium,
chloride) were stable during all treatments (Table 2). Low
dialysate magnesium (0.5 mmol/l) reduced average sys-
temicmagnesiumconcentrations.Despitethis,allmeasured
magnesiumvalueswerewithinthenormalrange.Thebicar-
bonate concentration in the dialysis solution was adjusted
during the treatments according to the monitored pH. Us-
ing this approach, no alkalosis or acidosis was observed.
The changes of acid–base status during the treatment were
typical for bicarbonate-based dialysis (Table 2). Also af-
ter the treatment, acid–base values remained within normal
range. Despite metabolism of citrate increasing bicarbon-
ate concentration alkalosis did not develop in any of the
patients.
Discussion
Anticoagulation for chronic dialysis patients with con-
traindications to heparin administration (risk of bleeding or
heparin-inducedthrombocytopaeniatype2,HIT-2)remains
challenging. The regimens used alternatively, e.g. regional
heparinization with protamine, direct thrombin inhibitors,
prostacyclin or anticoagulation-free dialysis, encounter
considerable limitations. Whether because of expense, lack
of effectiveness or complexity, neither of them has gained
widespreadacceptance.Regionalcitrateanticoagulationof-
fersadvantages,whichcouldmakeitafirst-choiceregimen
for alternative anticoagulation. Citrate anticoagulation not
onlyreducesbleedingrisk[9,10]butalsocanbemoreeffec-
tive than heparin in preventing thrombus formation in the
dialysis circuit [11]. Furthermore, a depletion of calcium in
the extracorporeal circuit during RCA is known to attenu-
ateneutrophildegranulation,andthusmayreduceoxidative
stress [12]. Despite many recognized advantages, only few
dialysis centres apply citrate anticoagulation on a routine
basis, primarily because the relationships between citrate
infusion, calcium levels and dialysis parameters are com-
plex. Although numerous protocols have been published so
far, a generally accepted standard prescription of RCA for
haemodialysis has not yet evolved. In addition, the appli-
cation of RCA is cumbersome because it usually requires
additional pumps for citrate and calcium infusions, which
are not provided by standard dialysis machines. These is-
sues not only increase the complexity of the RCA proce-
dure but also the likelihood of complications, which may
occur more frequently if the method is rarely used [13].
Of the possible complications, the most dangerous is sys-
temic hypocalcaemia, since it can cause life-threatening
arrhythmias.
Thisstudypresentscitrateandcalciumpharmacokinetics
during high-flux dialysis, which to our knowledge, has not
yet been investigated in detail during this type of treatment.
The results of this investigation may help to better under-
stand possible mechanisms disturbing calcium homeosta-
sis and shows a rationale approach for calcium substitution
during high-flux dialysis.
Most frequently, an increase in systemic citrate concen-
tration is suspected as a cause of hypocalcaemia during
citrate anticoagulation. We observed that during high-flux
dialysis, systemic citrate concentrations had a high margin
of safety. All measured citrate values were well below the
level of 2.5 mmol/l known to be toxic for heart function in
case no calcium supplementation is carried out [14]. More-
over, citrate concentrations were also lower than reported
during aphaeresis procedures where in contrast to dialy-
sis calcium is not routinely supplemented [15–17]. Earlier
studies in dialysis, in which comparable doses of citrate
were used, reported higher systemic citrate concentrations
as well [18]. Lower citrate concentrations in our study are
most likely due to the use of high-flux dialysers removing
83% of the infused citrate. Using these dialysers, clearance
of citrate constituted ∼60% of total urea clearance for a
blood flow of 180–200 ml/min, a ratio similar to published
data [2].
As other investigators of citrate pharmacokinetics, we
assumed citrate metabolism to follow first-order kinetics
[19–21]. It can be argued that estimation of citrate half-life
using a two-compartment model may be more appropriate
than using post-treatment citrate concentrations. If a two-
compartment model is used, then citrate half-life differs by
<10% (55 ± 25 min versus 60 ± 29 min). Independently
from the method used, citrate half-life in our patients was
longerthanthosereportedbyApsneretal.andKrameretal.
in the control groups with normal kidney function (33 and
36 min) [19,20]. Similar results in renal failure patients
have already been reported by Bauer et al. (49 min) [21].
Thus, it would be tempting to say that renal failure might
be associated with impaired citrate metabolism, which is,Kinetics of citrate anticoagulation during dialysis 2249
however, in contrast to the conclusion made by Bauer et al.
In this study, citrate half-life in the end-stage renal failure
patients did not differ significantly from the results of the
control group without renal failure (59 min). The clinical
characteristics of this control group were similar to that of
thestudybyApsneretal.(patientswithautoimmuneorlipid
disturbances undergoing immune- or lipidapheresis) [19].
It remains at present unclear why citrate half-lives differ so
much in similar patient groups. Also the question whether
haemodialysis patients have impaired citrate metabolism
requiresfurtherclarificationinfuturestudies.Nevertheless,
during high-flux dialysis, citrate metabolism is of minor
importanceasthedialysisprocedureiseffectivelyremoving
citrate and only little needs to be metabolized. This amount
was successfully metabolized in our patients and did not
accumulatebetweentreatments.However,theroleofcitrate
metabolism could be more important during continuous
dialysis modalities, because of a larger total load of citrate,
which is delivered over a longer treatment time compared
to intermittent HD [4].
Another parameter that may influence systemic citrate
levels is the distribution volume of citrate. A lower vol-
ume of distribution will result in higher plasma levels of
citrate. According to our data in stable dialysis patients
during 4 h of dialysis, citrate is easily distributed within
a large volume (∼40 l). Thus, in adult patients the effect
of distribution volume on citrate concentration is limited.
However, we observed that in the first 2 h of dialysis the
distribution of citrate was not yet in a steady state, which
probably contributed to the more rapid increase in systemic
citrate concentration over this time. The apparent volume
of distribution after 4 h of treatment was very reminiscent
to the estimate of the total body water known for healthy
people(54%ofthebodyweight).Nevertheless,aninterpre-
tation of distribution in terms of body water compartments
requires caution, as dialysis patients may have varied hy-
drationstatusandwatercompartmentscomparedtohealthy
people.Otherauthorsreportedsmallerdistributionvolumes
of citrate [19,20]. However, in previous studies, citrate was
administeredoverashortertime(120minversus240minin
our study). This may potentially lead to a lower distribution
volume, as a disposition of a substance is a time-dependent
process. In addition, it should be emphasized that distri-
bution patterns may differ significantly depending on the
clinical characteristics of the studied population, e.g. criti-
cally ill patients as studied by Kramer et al. [20] may suffer
fromnumerousconditionspotentiallyaffectingdistribution
patterns such as impaired microcirculation, varying degree
of oedema or even dehydration. Thus, our results of cit-
rate distribution should not be extrapolated to other patient
populations, e.g. critically ill patients.
In summary, if high-flux dialysers are used, elimina-
tion of citrate by dialysis constitutes the major elimina-
tion pathway of citrate, whereas metabolic degradation of
citrate is of minor importance. Small amounts of citrate
reaching systemic circulation are easily distributed within
a large volume resulting in only low increases in systemic
citrate concentrations. These small increases are probably
well buffered by shifts of calcium ions from proteins and
therefore no measurable decreases of ionized calcium are
detected. Aphaeresis studies provide additional evidence
that systemic citrate concentrations <1.0 mmol/l do not
measurably decrease ionized calcium and are well tolerated
withoutcalciumsupplementation[15,17].Inlinewiththese
observations, in our study calcium supplementation corre-
lated strongly with calcium removal (r = 0.797, P < 0.001)
indicatingthattheriskofhypocalcaemiaduringcitrateanti-
coagulation is mainly associated with calcium dialytic loss.
Thus, identifying factors influencing calcium removal is
important, in order to improve the accuracy of calcium sup-
plementation. Two major parameters determined calcium
loss: (1) total serum calcium concentration prior to dialysis
and (2) clearance of the citrate–calcium complexes.
(1) The influence of total serum calcium is due to the
fact that calcium removal is determined by diffusible
calcium that in turn depends on total calcium concen-
tration. Diffusible calcium inside the dialyser was a
constant fraction of total calcium (80 ± 3%). Because
of the constant relation of diffusible to total calcium,
total calcium is an important determinator of calcium
removal.
(2) Clearanceofthecitrate–calciumcomplexesisthesec-
ond key parameter influencing calcium removal and
substitution.Themajorityofcitrateanionswerebound
to calcium; thus the measured citrate clearance was
rathertheclearanceofcitrate–calciumcomplexes.Ob-
viously, as with all dialysis procedures, dialyser sur-
face area, permeability of the dialyser as well as blood
and dialysate flow rates, all effect the clearance of a
solute, in this case of citrate–calcium complexes. For
the purpose of this study, these dialysis parameters
were kept similar during all dialysis sessions (dialy-
sers with the same clearance characteristics, a fixed
dialysate flow rate of 500 ml/min and the blood pump
speed of 200 ml/min in all patients). Despite simi-
lar blood flow and other dialysis parameters, patients
experienced different citrate clearances and different
calcium removal. The relevant patient parameter in-
fluencingclearanceofcitrate–calciumcomplexes was
haematocrit. In contrast to urea, citrate is not enter red
blood cells [22]. Therefore, citrate clearance corre-
lated more closely with plasma flow than with blood
flow. At a given blood flow rate (183 ml/min), pa-
tients with a lower haematocrit had a higher plasma
flow rate, thus a higher clearance of citrate–calcium
complexes and a higher removal of calcium. For this
reason, patients with a lower haematocrit required a
higher calcium substitution rate during citrate antico-
agulation.
Our data indicate that the risk of hypocalcaemia during
citrate anticoagulation can be reduced substantially, if neg-
ative calcium balance is avoided by supplementing calcium
at a rate not lower than calcium removal. Since calcium
removal is so important in guiding calcium substitution
and its direct measurement is not practicable in routine
dialysis, we developed a nomogram (Figure 3) that allows
estimation of calcium removal based on clinically available
parameters, total calcium concentration and haematocrit,
provided that other dialysis parameters are kept constant
(type of dialyser, blood and dialysate flow rate). Using this2250 J. Kozik-Jaromin et al.
Fig. 3. Nomogram of calcium removal (mmol/h) calculated for different
haematocritandtotalcalciumconcentrationsusingdialyserF60S(KoAfor
citrate: 337 ml/min), blood pump speed: 200 ml/min (effective blood flow
rate:180ml/min),dialysateflowrate:500ml/min,proteinconcentration=
6.5 g/dl.
nomogram(Figure3),itcanbepredictedthatifhaematocrit
is low (<0.3) and total calcium is in the normal range (2.2–
2.6 mmol/l), a calcium substitution rate of 12 mmol/h will
be insufficient to replace calcium losses. This was con-
firmed in two patients with low haematocrit in our study.
In contrast, patients with higher haematocrit (≥0.45) re-
quire less calcium substitution than 12 mmol/h if they have
normal total calcium.
The presented nomogram on calcium removal can be
used to estimate a required starting dose of calcium
supplementation. At present, it is a frequent practice to
use the same initial calcium supplementation rate and
then to adjust it to the measured ionized calcium level.
We propose to consider calcium dialytic loss for the
choice of the initial calcium supplementation rate in
order to avoid hypocalcaemia due to negative calcium
balance or calcium overdosing due to highly positive
calcium balances. This approach can help to estimate the
initialcalciumsupplementationbutdoesnotreplaceionized
calcium measurements to confirm the accuracy of calcium
dosing since metabolic conditions of patients may change
calcium supplementation requirements in addition to cal-
cium dialytic loss, e.g. due to the development of alkalo-
sis or acidosis. In addition, ionized calcium measurements
are sometimes the only safety measures to detect equip-
ment malfunctions or handling errors that may also lead
to hypocalcaemia such as reversing of citrate and calcium
infusions [13]. Thus, an adequate calcium substitution and
calciummonitoringarethemostimportantsafetymeasures
during citrate anticoagulation.
The strength of the proposed calcium substitution ap-
proach is that in contrast to fixed dosing schemes it also
considerspatientcharacteristicsandhelpstoavoidhypocal-
caemia from the beginning of dialysis, particularly in pa-
tientswithalowhaematocritand/orhightotalcalciumlevel.
Calcium substitution rates based on the nomogram will re-
sult in a small positive calcium balance. This is due to the
use of an in vitro value of KoA for citrate in our equation
for calcium removal and substitution. In vitro KoA values
are typically higher than values reached in vivo. Positive
calcium balance provides an additional safety margin to
avoid hypocalcaemia and is comparable to conventional
dialysis. During conventional haemodialysis, patients also
receiveacalciumloadsincecalciumconcentrationsinstan-
dard dialysis solutions are higher than ionized calcium in
the blood [18]. Positive calcium balance was well tolerated
in this study. There is ongoing concern, however, whether
a positive calcium balance during dialysis may have detri-
mental effects, e.g. calcification of soft tissues and blood
vessels. If desired, both anticoagulation methods can eas-
ily achieve a neutral or negative calcium balance using a
lower calcium content of the dialysate or a lower calcium
substitution rate, respectively.
The limitation of the presented calcium nomogram
(Figure 3) is that it is valid only for certain fixed dialysis
settings (dialyser F60S, blood pump speed of 200 ml/min
and dialysate flow rate of 500 ml/min). Many variations
of a dialysis technique are possible. If different dialysers,
bloodordialysateflowratesareused,thendifferentremoval
of calcium and thus substitution rate have to be expected
and the nomogram needs to be modified by the user. We
used a blood pump speed of 200 ml/min, which had already
been successfully applied during citrate anticoagulation by
other authors [23–25]. Using this blood flow rate, partic-
ularly in large patients, an adequate weekly dialysis dose
will be provided either with the longer treatment time, e.g.
6 h per session or with daily dialysis, which is common
in the intensive care setting. In the nomogram, we also did
notincludetheeffectofserumproteinconcentrationoncal-
ciumlosses.Atagivenhaematocritandtotalserumcalcium
concentration, a low protein level (<5 g/dl) may result in a
higher proportion of diffusible calcium inside the dialyser
(84%insteadof80%)andthusinahighercalciumremoval.
Therefore, we suggest increasing the calcium supplemen-
tation rate given by the nomogram by 4% in patients with a
protein level of <5 g/dl.
It is important to note that this model of calcium re-
moval and substitution is not applicable to continuous renal
replacement therapies in intensive care patients. In this set-
ting, citrate anticoagulation is carried out over a longer
period of time leading to a higher total citrate load. Lower
clearance rates typical for continues treatments will reduce
citrate removal increasing systemic citrate levels compared
to intermittent HD. Furthermore, critically ill patients may
have difficulties to metabolize this high citrate load due to
reduced liver function or impaired distribution of citrate.
Therefore, during continuous treatment modalities, other
approaches to estimate calcium dosing during citrate anti-
coagulation are required.
In conclusion, during high-flux dialysis systemic citrate
loadandcitrateplasmaconcentrationsareverylow.Thus,in
theory, citrate anticoagulation during intermittent dialysis
should also be safe in patients with impaired liver function
[26], but this requires further studies. In contrast, calcium
losses due to the use of calcium-free dialysis solution are
substantial. Hypocalcaemia is likely to develop if calcium
substitution is less than dialytic removal. Matching cal-
ciumsupplementation todialyserremovalisthebestwayto
prevent both calcium overload and hypocalcaemia, respec-
tively.AnomogramisprovidedtoestimatecalciumremovalKinetics of citrate anticoagulation during dialysis 2251
based on total calcium concentration and haematocrit as-
suming the use of a typical high flux dialyzer (Fresenius
F60S), a blood pump speed of 200 ml/min and a dialysate
flow of 500 ml/min. Calcium removal based on the nomo-
gram can be used as a surrogate for the choice of the initial
calcium substitution rate (Figure 3). Use of this nomogram
will, in addition to calcium monitoring, reduce the risk of
hypocalcaemia during citrate anticoagulation. Since an in-
dividual variability in metabolism and disposition of citrate
and calcium as well as malfunctions of the used equipment
cannot be excluded, monitoring of ionized calcium during
citrate anticoagulation remains indispensable.
Ourdataclarifysomeimportantaspectsofcitrateandcal-
cium kinetics e.g. the dependence on haematocrit and total
serumcalcium concentration of the patient. The knowledge
ofcitrateandcalciumpharmacokineticsandtheuseofmod-
ern dialysis machines with integrated citrate and calcium
pumpsmaymaketheapplicationofthisvaluableanticoagu-
lation method easier and thus available to a broader number
of patients.
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